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Insulin signalingHepatic steatosis is often associated with insulin resistance as a hallmark of the metabolic syndrome in the liver.
The present study investigated the effects of PPARα activation induced by fenoﬁbrate (FB) on the relationship of
insulin resistance and hepatic steatosis inmice fed a high-fat (HF) diet, which increases lipid inﬂux into the liver.
Mice were fed HF diet to induce insulin resistance and hepatic steatosis with or without FB. FB activated PPARα
and ameliorated HF diet-induced glucose intolerance and hepatic insulin resistance without altering either
hepatic steatosis or inﬂammation signaling (JNK or IKK). Interestingly, FB treatment simultaneously increased
fatty acid (FA) synthesis (50%) and oxidation (66%, both p b 0.01) into intermediate lipidmetabolites, suggesting
a FA oxidation-synthesis cycling in operation. Associated with these effects, diacylglycerols (DAGs) were
sequestered within the lipid droplet/ER compartment, thus reducing their deposition in the cellular membrane,
which is known to impair insulin signal transduction. These ﬁndings suggest that the reduction in membrane
DAGs (rather than total hepatic steatosis) may be critical for the protection by fenoﬁbrate-induced PPARα
activation against hepatic insulin resistance induced by dietary fat.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Consumption of a high-fat (HF) diet is an important nutritional
factor leading to the development of insulin resistance due in part to
the resultant accumulation of lipids in key insulin target organs [1,2].
While muscle is quantitatively the major site contributing to whole-
body insulin resistance, lipid accumulation and insulin resistance often
occur in the liver prior to muscle in response to dietary HF [3]. More-
over, factors derived from the liver such as lipids and cytokines may
have distal inﬂuence on other insulin-responsive tissues [4].ulin-receptor-substrate 1; FB,
roxyacyl-CoA dehydrogenase;
3β, glycogen synthase kinase;
, acetyl-CoA carboxylase; SCD-1,
se 1; RER, respiratory exchange
kinase C; JNK, c-Jun N-terminal
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hould be considered as co-ﬁrstInsulin resistance in the liver can be closely associated with hepatic
steatosis in both human and rodents [2,5–7]. It has been suggested
that increased lipid metabolites such as diacylglycerols (DAGs) and
ceramides in hepatic steatosismay be the keymediators of insulin resis-
tance as they can interrupt insulin signaling transduction [8]. However,
some studies also indicated that hepatic steatosis may occur indepen-
dently of insulin resistanceunder certain conditions [9,10]. For example,
mice with overexpressed diacylglycerol acyltransferase (DGAT) in the
liver retained normal response to insulin action despite the accumula-
tion of these lipids in this organ [11]. It has been proposed that the cel-
lular location of DAGs may play a key role in hepatic insulin resistance
[12] because DAGs need to recruit protein kinase Cϵ (PKCϵ) from the cy-
tosol tomembrane and activate it at this site to interferewith the insulin
signaling pathway [1,13]. These studies suggest that other factors may
be involved in lipid-induced insulin resistance in the liver apart from
the total content measured at the tissue level.
Recently, we have found that activation of peroxisome proliferator-
activated receptor α (PPARα) eliminates hepatic insulin resistance by
decreasing hepatic steatosis and DAGs content in high-fructose (HFru)
fed mice [14]. The HFru mouse is a well-characterized model [13] that
mimics the hepatic insulin resistance resulting from excess de novo li-
pogenesis within the liver from high sucrose in humans [15]. However,
it is not knownwhether activation of PPARα also exerts the same effect
on hepatic insulin resistance in HF fed mice. In contrast to HFru mouse
1512 S.M.H. Chan et al. / Biochimica et Biophysica Acta 1852 (2015) 1511–1519model, the HF model represents overconsumption of dietary fat in
humans. In this model, the hepatic steatosis is induced by the inﬂux of
exogenous lipids rather than de novo lipogenesis within the liver [13].
Here we report that activation of PPARαwith fenoﬁbrate (FB) ame-
liorates HF-induced hepatic insulin resistance without a reduction in
hepatic steatosis or the total level of DAGs. Instead, FB treatment sig-
niﬁcantly reduces the content of DAGs in the cellular membrane by
sequestering these lipid metabolites within the lipid droplet/ER com-
partment. As cellularmembrane attachedDAGs are known to impair in-
sulin signal transduction [8], our ﬁndings indicate that activation of
PPARαwith FB in HF-fedmice can ameliorate hepatic insulin resistance
by re-compartmentalization of DAGs in the liver cell in respect of
steatosis and the overall DAG content in this organ.
2. Materials and methods
2.1. Animal study
All experiments were approved by the Animal Ethics Committees of
the RMIT University (#1206). Male C57BL/6J mice (13 weeks) from the
Animal Resources Centre (Perth, Australia) were kept at 22 ± 1 °C on a
12-h light/dark cycle. Mice were fed ad libitum for two weeks with ei-
ther a chow (CH 10% calories from fat) or fat-rich (HF; 45% calories
from lard) diet as previously described [14,16] with or without
fenoﬁbrate (FB; Sigma-Aldrich, Australia) at 100 mg/kg/day in the
diet. Glucose tolerance tests (GTT; 2.5 g glucose/kg i.p.) were performed
on 4 h fasted mice. Blood glucose levels were monitored using a
glucometer (Accu-Chek Performa Nano, Roche) and blood samples
were collected at 0, 30 and 60 min for plasma insulin measurement by
radioimmunoassay (Linco/Millipore, Billerica). Insulin signaling trans-
ductionwas assessed by the response to an i.p. injection of insulin as de-
scribed in our previous studies [14,16].
2.2. Metabolic measurements
The effect of FB treatment on whole-body metabolic rates was
assessed at 22 °C using a Comprehensive Laboratory Animal Monitoring
System (CLAMS, Columbus Instruments, USA) as described previously
[17]. 10-Week old mice fed with CH or HFru diet, with or without FB,
were acclimatized in the CLAMS for 2 h. O2 consumption and CO2 pro-
duction were continuously monitored for 12 h.
Hepatic de novo lipogenesis (DNL) was measured by the incor-
poration of [3H]–H2O into triglyceride (TG) in the liver as describedTable 1
Effects of fenoﬁbrate on whole-body energy, lipid and glucose metabolism.
CH CH-FB
Body mass (g)
Day 0 27.0 ± 0.3 27.0 ±
Day 14 28.0 ± 0.4 28.0 ±
EPI fat mass (% BW) 1.3 ± 0.1 1.0 ±
Caloric intake (kcal/day) 12.0 ± 0.1 12.2 ±
VO2 (l/kg·h) 3.1 ± 0.1 3.4 ±
RER 0.94 ± 0.01 0.95 ±
Blood glucose (mM) 8.8 ± 0.4 9.1 ±
Plasma insulin (pg/ml) 203 ± 23 91 ±
HOMA-IR 77.4 ± 9.0 40.1 ±
Plasma triglyceride (μM) 354 ± 20 176 ±
Male C57BL/6J mice were fed either a chow (CH) or high fat (HF) for 2 weeks with the PPARα
oxygen consumption rate, RER — respiratory exchange rate, HOMA-IR — homeostatic model a
⁎ p b 0.05.
⁎⁎ p b 0.01 vs corresponding control group.
† p b 0.05.
†† p b 0.01 vs CH-FB group.
‡ p b 0.05.
‡‡ p b 0.01 vs CH.previously [14]. Hepatic FA oxidation was measured in separate liver
homogenates using [1-14C] palmitate as described previously [14]. Sep-
arately, 20 mg of frozen liver tissue was homogenized in 175 mM KCl
and 1.98mMEDTA containing buffer (pH 7.4)with a glass homogenizer
for the measurement of citrate synthase and β-hydroxyacyl-CoA
dehydrogenase (β-HAD) activities [14,16]2.3. Hepatic TG and long chain acyl-CoA (LCACoA)
Liver TG was extracted by the method of Folch and determined by a
TG GPO-PAP kit (Roche Diagnostics, Australia) as previously described
[16]. Long-chain acyl-CoA (LCACoA) levels in the tissue were measured
using methods described previously with slight modiﬁcations. Approx-
imately 30 mg of tissue was homogenized in a 1.2 ml ice-cold 10% tri-
chloroacetic acid. After centrifugation and washing, 250 μl of 10 mM
dithiothreitol was added and the pH was raised to 11.5 with 1 M KOH.
The thioester bondswere hydrolyzed at 55 °C for 10min before neutral-
ization with 1 M hydrochloric acid. Samples were buffered to a ﬁnal
concentration of 50 mM KPO4, and cleared of debris by repeated centri-
fugation. For quantiﬁcation, a ﬂuorescence reading was taken prior to
addition of enzyme, and then again after addition of 20 mU of α-
ketoglutarate dehydrogenase (Sigma-Aldrich, Australia). The change
in ﬂuorescence was used to calculate LCACoA concentration in the
samples.2.4. Fractionation and analyses of hepatic lipids
Cellular compartmentswere fractionated using sucrose gradient and
differential centrifugations [12]. Liver tissue was homogenized in buffer
A (20 mM Tris HCl, 1 mM EDTA, 0.25 mM EGTA, 250 mM sucrose, pro-
tease and phosphatase inhibitors), and 3% sucrose was topped on the
homogenate. Samples were centrifuged for 1 h at 100,000 ×g. The
lipid droplet fraction was carefully removed and saved. The middle
layerwhich is the cytoplasm fractionwas removed and saved. The pellet
was re-suspended with buffer A for DAG analysis or buffer B (20 mM
Tris HCl, 150 mM NaCl, 50 mM NaF, 5 mM NaPPi, 1 mM EDTA,
1 mM EGTA, 1 mM PMSF, protease and phosphatase inhibitors) for
protein analysis. These samples were then centrifuged for 15 min
at 20,800 ×g. The ﬂoating lipid was removed and combined with
previous lipid droplet fraction. The supernatant contained rich plas-
ma membrane. Triton-X was added to the supernatant for protein
analysis. Diacylglycerol (DAG) and ceramide were extracted andHF HF-FB
0.4 27.1 ± 0.3 26.8 ± 0.4
0.4 30.0 ± 0.5‡ 27.0 ± 0.6⁎⁎
0.1 3.3 ± 0.3‡‡ 1.2 ± 0.1⁎⁎††
0.1 17.1 ± 0.5‡‡ 18.0 ± 0.5⁎⁎
0.1⁎⁎ 3.5 ± 0.1‡‡ 3.5 ± 0.1⁎⁎
0.01 0.86 ± 0.01‡‡ 0.81 ± 0.01⁎⁎††
0.4⁎ 11.8 ± 0.5‡ 10.5 ± 0.5⁎†
16⁎⁎ 313 ± 64‡‡ 100 ± 13⁎⁎††
7.0⁎⁎ 166.2 ± 37.5‡‡ 47.3 ± 6.8⁎⁎††
10⁎⁎ 345 ± 24 159 ± 12⁎⁎††
agonist fenoﬁbrate (FB, 100 mg/kg/day in diet). Veh — vehicle, EPI — epididymal, VO2 —
ssessment of insulin resistance. Data are means ± SE of 8–12 mice per group.
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lation analyzer (LS6500, Beckman Coulter Inc, USA).2.5. Western blotting
The protein samples were separated by SDS-PAGE for western blot-
ting analysis [14] using speciﬁc antibodies: total- and phospho
(Ser473)-Akt, total- and phospho (Ser219)-glycogen synthase kinase
3β (GSK3β), acyl-coenzyme A oxidase 1 (ACOX1), sterol regulatory
element-binding protein 1c (SREBP1c), acetyl-CoA carboxylase (ACC),
fatty acid synthase (FAS), stearoyl-CoA desaturase 1 (SCD-1), total-
and phospho (Th183)-JNK, total- and phospho (Ser176)-IKKα/β.
Immunolabeled bands were quantiﬁed by densitometry (ImageLab,
Bio-Rad Laboratory, USA) and representative blots are shown.Fig. 1. Fenoﬁbrate corrected glucose intolerance and hepatic insulin signal transduction. After t
feeding, (A) glucose tolerance test (GTT; 2.5 g glucose/kg BW, i.p.) was performed with increm
insulin levels between 30 and 60min of GTT. Insulin (2 U/kg BW, i.p.) was injected 20min befo
phosphorylated- and total-Akt (Ser473; top panel), phosphorylated- and total- GSK3β (Ser9;
(E). Data are means ± SE of 6 to 8 mice per group. * p b 0.05; ** p b 0.01 vs CH; † p b 0.05; †† p2.6. Statistical analyses
Data are presented asmeans±SE. One-way analysis of variancewas
used for comparison of the relevant groups. When signiﬁcant differ-
ences were found, the Tukey–Kramer multiple comparisons test was
applied. Differences at p b 0.05 were considered to be statistically
signiﬁcant.
3. Results
3.1. Fenoﬁbrate preserved glucose tolerance and hepatic insulin
signaling in HF-fed mice
In the absence of fenoﬁbrate (FB) treatment (HF group), mice
displayed metabolic characteristics that are typical of HF feeding,wo weeks of chow (CH), chowwith FB (CH-FB), high fat (HF) or high fat with FB (HF-FB)
ental area under the curve (iAUC) for blood glucose level shown on the right. (B) Plasma
re tissue collection to assess hepatic insulin signal transduction. (C) Representative blots of
bottom) with GAPDH as a loading control. Densitometry analyses are shown in (D) and
b 0.01 vs HF.
Fig. 2. Fenoﬁbrate stimulated the hepatic de novo synthesis of FA. Hepatic de novo lipogenesis (DNL)wasmeasured by the incorporation of [3H]–H2O into triglyceride (A). Representative
blots of key enzymes for FA synthesis (B):matured form of SREBP1c (mSREBP1c), ACC, FAS and SCD1with the respective densitometry (C–F). * p b 0.05; ** p b 0.01 vs CH; †† p b 0.01 vsHF.
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duced respiratory exchange ratio (RER; p b 0.01 vs CH; Table 1) and glu-
cose intolerance (Fig. 1A–B). Consistent with these changes, the hepatic
insulin signaling transduction was impaired as evidenced by the
blunted phosphorylation of Akt and its downstream effector GSK3β in
response to the stimulation of insulin injection (Fig. 1C–E). In CH-fed
mice, FB treatment had no signiﬁcant effects on body weight gain, adi-
posity, caloric intake or RER except for a 9% increase in VO2 (p b 0.01
vs CH). FB treatment of HF-fed mice attenuated (p b 0.01 for all) the
diet-induced body weight gain and visceral adiposity, while RER was
further reduced suggesting a further shift towards FA as the predomi-
nant energy source (Table 1). Glucose tolerance and hepatic insulin sig-
naling (and muscle; data not shown) were restored to similar levels of
CH-FB in the HF-FB group (Fig. 1C–E). FB treatment also reduced the re-
quirement for plasma insulin during GTT (Fig. 1B).
3.2. Fenoﬁbrate reversed the suppression on DNL in HF-fed mice
As DNL in the liver has been reported to be closely related to the in-
duction of UPR signaling [18], and activation of PPARα has been report-
ed to stimulate hepatic DNL [14,19], we examined lipogenicmetabolism
in response to the treatment of the PPARα activator FB in the HF-fed
mice. The exogenous supply of FAs in the HF diet resulted in a 27% re-
duction (p b 0.01 vs CH) of [3H]–H2O incorporation into TG indicating
suppressed DNL (Fig. 2A). Despite a two-fold increase in the expression
of the mature form of SREBP1c (mSREBP1c, Fig. 2B–C), HF feeding did
not alter the expression of downstream key enzymes for DNL such as
ACC, FAS and SCD1 (Fig. 2D–F). FB treatment increased DNL by 50% in
both feeding conditions (both p b 0.01 vs respective control; Fig. 2A).
Consistent with this, the expression of key enzymes for DNL and FAelongation was markedly increased by FB treatment regardless of diet
(all p b 0.01 vs respective control; Fig. 2B–F) indicating that FB treat-
ment enhances DNL independent of diet.
3.3. Fenoﬁbrate increased hepatic FA oxidation in the liver
The expression of ACOX1 which is directly under the regulation of
PPARα, was markedly increased (~13-fold vs respective control,
p b 0.01) in response to FB treatment (Fig. 3A), conﬁrming the activation
of PPARα in the liver. In accordance with the reported action of FB [14,
20], themice displayed lower plasma TG levels (Table 1). HF feeding re-
sulted in a 58% and 21% (both p b 0.01 vs CH) increase in the activity of
β-HAD (Fig. 3B) and citrate synthase (Fig. 3C), respectively. FB treat-
ment of the HF-fed animal further augmented the activity of β-HAD
by 50% (p b 0.05 vs HF) without affecting the citrate synthase activity
(Fig. 3B–C). As β-HAD catalyzes the third step of mitochondrial β-
oxidation, its increased activity suggests an enhanced FA oxidation by
FB treatment. Accordingly, HF feeding increased hepatic FA oxidation
by 68% (p b 0.01 vs CH) which was further increased by FB treatment
(p b 0.01 vs respective control, Fig. 3D). Fractionation analyses revealed
that the further augmentation of FA oxidation in FB treated mice was
due to incomplete oxidation (the acid soluble fraction, Fig. 3E) rather
than complete oxidation (the CO2 fraction, Fig. 3F).
3.4. Fenoﬁbrate induced re-compartmentalization of DAGs
independent of hepatic steatosis
HF feeding alone increased hepatic TG (2-fold; Fig. 4A) and LCACoA
content (2.5-fold; all p b 0.01 vs CH; Fig. 4B). Therewas a 50% increase in
DAG content (p b 0.01 vs CH; Fig. 4C) while ceramide was unaltered
Fig. 3. Fenoﬁbrate increased hepatic FA oxidation. The hepatic expression of ACOX1with densitometry (A). The speciﬁc activities of β-HAD (B), and citrate synthase (C). (D) Hepatic fatty
acid (FA) oxidationwith fractional analyses: (E) the acid soluble fraction contains the incompletely oxidized FA intermediateswhile (F) the CO2 fraction captures complete oxidation. Data
are means ± SE of 6 to 8 mice per group. * p b 0.05; ** p b 0.01 vs CH; † p b 0.05; †† p b 0.01 vs HF.
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treatment did not reduce the total content of these lipids in the liver ho-
mogenate (Fig. 4A–D). The phosphorylation of JNK and IKK in the liver
was not signiﬁcantly affected by HF feeding or administration of FB
(Fig. 4E–F).
As intracellular compartmentalization of DAG rather than total
content per se is thought to be a key determinant of lipotoxicity [12],
we further examined whether FB treatment may alter the partitioning
of DAGs into different intracellular compartments. As shown in Fig. 5C,
HF feeding markedly increased DAG accumulation in the plasma
membrane-enriched fraction (2-fold; p b 0.01 vs CH) and this was
completely abolished by FB treatment. In contrast, DAGswere preferen-
tially enriched within the lipid droplet/ER compartment in response to
PPARα activation (Fig. 5B). Unlike HF mice, FB treatment increased
DAG storage in lipid droplet/ER fraction in CH-mice without reducing
membrane DAG (Fig 5 B–C). This may be due to a greater contribution
from the de novo lipogenesis (as shown in Fig 2A) at the ER in addition
to the intracellular re-compartmentalization of DAGs. In comparison, no
signiﬁcant changes in ceramide compartmentalizationwere detected in
the lipid droplets/ER or the membrane fraction, while an increase in
cytoplasmic ceramide content was observed (by 50%; p b 0.05 vs HF)
with FB treatment.
4. Discussion
The present study investigated the effect of PPARα activation with
FB on the interrelationship of insulin resistance and hepatic steatosisin HF fed mice. Our data showed that FB treatment activated
PPARα and increased FA oxidation. At the same time, FB treatment
is also able to overcome the inhibitory effect of HF diet on hepatic
lipogenesis. Although hepatic steatosis remained unresolved, the
parallel actions of FB treatment on oxidation and lipogenesis may
promote the re-distribution of DAGs from the plasma membrane to-
wards lipid droplet/ER, hence rectifying hepatic insulin signal trans-
duction in the HF-fed mice. These data provide new insights into the
regulatory role of PPARα on hepatic lipid metabolism in relation to
insulin sensitivity.
Ectopic accumulation of lipid outside adipose tissue, such as the
liver, is a major factor leading to impaired insulin sensitivity [21].
PPARα activation by FB has been demonstrated to reduce hepatic
steatosis in human [22] and rats [23], with mixed results in mice [19,
24] indicating possible species speciﬁcity effects. Our data showed a
marked increase in FA oxidation FB treatment. Unexpectedly, hepatic
steatosis remained in the HF-fed mice. Further analysis revealed that
FB treatment only increased FA oxidation to acid-soluble metabolites
but not to CO2. This indicates that the increased oxidation of FAs is
incomplete during FB treatment as reported for peroxisomal β-
oxidation [25]. However, the incomplete FA oxidation by the peroxi-
some alone cannot explain the persisting hepatic steatosis observed in
HF-fed mice with FB treatment.
Interestingly, our data showed that activation of PPARα with FB is
able to signiﬁcantly stimulate hepatic DNL while counteracting the in-
hibitory effect of HF feeding on hepatic insulin signal transduction.
Our ﬁndings are consistent with the a previous study using stable
Fig. 4. Fenoﬁbrate did not correct hepatic lipid accumulation induced by HF-feeding. Total triglyceride content (A), total content of LCACoAs (B), total content of DAGs (C), total content of
ceramide (D), phosphorylated JNK (E) and phosphorylated IKK (F) in the liver homogenate. Data are means ± SE of 6 to 8 mice per group. ** p b 0.01 vs CH.
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taneously induces hepatic oxidation and synthesis of FAs in normal
mice in the liver [14,19]. We have recently demonstrated that
PPARα activation is able to reverse insulin resistance induced by
feeding of a HFru diet, despite a marked increase in DNL. This is
due to the ability of PPARα-driven FA oxidation to outpace that of
DNL leading to a net reduction of deleterious lipids and steatosis,
which in turn preserves insulin signal transduction in the liver [14].
However, in HF fed mice the FB-induced oxidation is unable to over-
come the combination of FA inﬂux from exogenous lipid oversupply
and the DNL, thus resulting in no improvement in hepatic steatosis. It
is likely that the incompletely oxidized FAs also provide immediate
substrates for the biochemical reaction of lipid synthesis. As lipid
synthesis is an energy costing process, the simultaneous increases
in oxidation and synthesis would be expected to increase energyconsumption. This may explain, at least in part, the reduced visceral
adiposity and RER observed in these mice as previously reported
during PPARα activation in rodents [25].
The surplus availability of FA during HF feeding increases the deliv-
ery of FAs to the liver. When caloric intake is in excess of metabolic re-
quirements, FAs are converted into TG for storage resulting in hepatic
steatosis [26]. Although TG itself is unlikely to be an active signaling
molecule, active intermediates derived from the TG biosynthetic path-
way are deleterious to glucose metabolism and insulin signal transduc-
tion. For example, LCACoAs are not only an immediate precursor for the
de novo synthesis of DAGs and ceramide [27], but they can also inhibit
the activity of glycogen synthase and glucokinase leading to impaired
glycogen synthesis. Likewise, hepatic DAGs and ceramide have been
reported to indirectly interfere with IRS tyrosine phosphorylation [7]
and Akt activation [28], respectively, leading to an inability of insulin
Fig. 5. Fenoﬁbrate reduced DAGs in the membrane compartment within the liver. DAG and ceramide contents in cytoplasmic fraction (A, D), lipid droplet/ER fraction (B, E), plasma
membrane fraction (C, F). Data are means ± SE of 6 to 8 mice per group. * p b 0.05; ** p b 0.01 vs CH; † p b 0.05; †† p b 0.01 vs HF.
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data showed that HF feeding increases the accrual of total TG,
LCACoAs and DAGs, but not ceramide, which was associated with
the development of hepatic insulin resistance and manifestation of
glucose intolerance. This is consistent with a recent report [3] show-
ing similar increase in hepatic lipid levels after 1 week of HF feeding
while no signiﬁcant changes in hepatic ceramide content were de-
tected until after 3 weeks. This suggests that ceramide is not a key
player in mediating hepatic insulin resistance at the early stage of
HF feeding. It has been suggested that HF feedingmay induce hepatic
insulin resistance via the inﬂammatory pathway [30,31]. Interesting-
ly, activation of PPARα has been shown to inhibit the activation of in-
ﬂammatory pathway in the liver [32]. However, the attenuated
hepatic insulin resistance in the present study cannot be attributed
to this mechanism in the absence of changes in inﬂammatory
markers such as JNK or IKK.
Although hepatic steatosis was unresolved, DAG was sequestered in
the lipid droplet/ER rather than appearing in the plasma membrane
under fenoﬁbrate treatment. Membrane-associated DAGs can recruit
novel protein kinases C (PKC) [13,33] (Fig. 6), particularly the epsilon
isoform to the insulin receptor leading to inhibition of the tyrosine ki-
nase activity and impaired insulin signal transduction in the liver [34].
Hence, the insulation of DAGs in the lipid droplets/ER may help to se-
quester the activity of PKCε andminimizing their disturbance on insulin
signal transduction in the liver [12]. The mechanism of how PPARα ac-
tivation by fenoﬁbrate insulates DAG in the lipid droplet/ER is presentlyunknown. However, this is likely to result from coordinated effects of
PPARα activation induced by FB on TGhydrolysis, the de novo synthesis
of DAGs and the esteriﬁcation of DAGs into TG. For example, activation
of PPARα has been reported to upregulate adipose triglyceride lipase
(which concerts TG to DAGs) in the liver [35], glycerol-3-phosphate
acyltransferase 1 (DGAT1 isoforms 3, 6 and 9) and lipin 2 for the synthe-
sis of DAGs [36]. Asmost of these enzymes are attached to the ER [35,37,
38], it is reasonable to speculate that up-regulation of these enzymes
may channel DAGs into the ER/lipid droplet compartment, particularly
when the substrates for DAGs were increased (indicated by increased
acid soluble fraction) in FB-treated HF mice. In addition, activation of
PPARα with FB in rats has been shown to down-regulate the latent
DGAT1 in the liver, which may also retain DAGs in the ER [39,40].
In summary, the present study showed that activation of PPARα
with FB ameliorates HF-induced hepatic insulin resistance without a
reduction in hepatic steatosis or the total level of DAGs. These ﬁndings
suggest that the reduction in membrane DAGs rather than hepa-
tosteatosis is the key for the protection by PPARα activation against
lipid-induced hepatic insulin resistance (Fig. 6). The re-compartmental-
ization of DAGs may be due to PPARα-induced simultaneous increases
in FA oxidation and synthesis.
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